Protein C News and Research

RSS

SARS-CoV-2 ORF7a mutation limits host immune suppression, finds study

Researchers have identified a high variability in the C-terminal end of ORF7a in SARS-CoV-2 sequences collected from around the globe. They noted that mutations result in a defective suppression of interferon and lowered replication rate.

25 Feb 2021

SNX-5422 could make an effective COVID-19 prophylactic, says study

SNX-5422 is a heat shock protein 90 (Hsp90) inhibitor currently undergoing clinical trials as a cancer therapeutic. A recent study examines the applicability of repurposing the drug towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication inhibition.

25 Feb 2021

Research shows effective strategy to target the SARS-CoV-2 spike protein

The virus that causes COVID-19 belongs to the family of coronaviruses, "corona" referring to the spikes on the viral surface. These spikes are not static - to infect cells, they change shapes.

25 Feb 2021

Research shows how antibodies attach to and block Zika virus

The Zika outbreak of 2015 and 2016 are having lasting impacts on children whose mothers became infected with the virus while they were pregnant.

25 Feb 2021

Study reveals molecular details of SARS-CoV-2 interactions with human cells

In order to infect cells, SARS-CoV-2, the virus that causes COVID-19, needs to insert itself into the membrane of human cells. New molecular models show what parts of SARS-CoV-2 are critical for that interaction, revealing new potential drug targets.

25 Feb 2021

Study reports lasting immune response in convalescent COVID-19 patients

Researchers report the cellular immune response of convalescent patients in Germany, who recovered from mild or moderate infection compared to that of healthy people with no history of COVID-19.

25 Feb 2021

COVID-19 Antigen Self-Test from Siemens Healthineers receives special approval in Germany for self-use by laypeople

Siemens Healthineers announced today that the CLINITEST Rapid COVID-19 Antigen Self-Test has received limited special approval from the Federal Office for Drugs and Medical Devices.

From Siemens Healthineers 25 Feb 2021

Neuroinvasiveness of SARS-CoV-2 shown by viral RNA and inflammation in the brain

A new study describes the results of a macaque study that showed the development of neurological features of inflammation, following infection by SARS-CoV-2.

25 Feb 2021

Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells

The clinical phenotype of COVID-19, caused by SARS-CoV-2, is remarkable for its wide range of severity among individual patients. Genetic variations are known to mediate part of these differences. To examine these differences, researchers in a new study used human induced pluripotent stem cells (iPSCs) from different genetically diverse individuals. These cells are used to model genetic disease since they contain the donor’s genetic information. Researchers use a panel of iPSCs from over 500 individuals. The researchers preferred undifferentiated iPSCs to reduce the time required to differentiate them, especially since infection is not always reliable.

25 Feb 2021

New hydrogel-based materials show promise for tissue engineering

New hydrogel-based materials that can change shape in response to psychological stimuli, such as water, could be the next generation of materials used to bioengineer tissues and organs, according to a team of researchers at the University of Illinois Chicago.

25 Feb 2021

Combination technique can toggle specific genes on and off

The genetic tool CRISPR has been likened to molecular scissors for its ability to snip out and replace genetic code within DNA.

25 Feb 2021

'Miracle poison' can target a variety of different proteins

Researchers prove they can engineer proteins called proteases to find new targets with high selectivity, a critical advance toward potential new treatments for everything from neuro-regeneration to cytokine storm.

25 Feb 2021

New book focuses on rational drug design and discovery

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery.

25 Feb 2021

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Researchers from the US recently compared antibody binding and viral neutralization against 2 SARS-CoV-2 variants that emerged in different parts of the world. The researchers used sera from spike mRNA vaccinated and naturally infected individuals against a circulating B.1 variant and the emerging B.1.351 variant. The study is published on the preprint server bioRxiv.

24 Feb 2021

Full characterization of mammalian-produced SARS-CoV-2 receptor binding domains

A research paper recently uploaded to the preprint server bioRxiv by Dominguez-Vega et al. (23rd Feb, 2021) describes an in-depth structural analysis of the RBD of the spike protein expressed in mammalian Chinese hamster ovary (CHO) cells and human embryonic kidney (HEK293) cells, providing a new understanding of protein structure and function.

24 Feb 2021

KTH researchers identify 300 proteins that regulate cell division process

With the hope of contributing to the fight against cancer, researchers in Sweden have published a new molecular mapping of proteins that regulate the cell division process - identifying 300 such proteins.

24 Feb 2021

Researchers discover a mechanism linked to stem cell aging

As people get older, their neural stem cells lose the ability to proliferate and produce new neurons, leading to a decline in memory function.

24 Feb 2021

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

Researchers in Italy have conducted a study showing that patients who had tested positive for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still had neutralizing antibodies against the virus 10 months later.

24 Feb 2021

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

24 Feb 2021

Using machine learning to identify blood biomarkers for early diagnosis of autism

Using machine learning tools to analyze hundreds of proteins, UT Southwestern researchers have identified a group of biomarkers in blood that could lead to an earlier diagnosis of children with autism spectrum disorder (ASD) and, in turn, more effective therapies sooner.

24 Feb 2021